Close

Ratings by Jefferies (Andrew Tsai)

Date CompanySymbol Type Rating
(Past)
PT
(Past)
Start $
(End $)
% Chg. Details
2/8/2024 Intra-Cellular Therapies ITCI Maintain Buy
(N/A)
 
 
  Details
2/6/2024 Vertex VRTX Maintain Hold
(Hold)
 
 
  Details
12/7/2023 VistaGen Therapeutics VTGN Upgrade Buy
(Hold)
4.29
(4.94)
15.15% Details
10/4/2023 POINT Biopharma Global Inc. PNT Downgrade Hold
(Buy)
6.68
(12.50)
87.13% Details
7/20/2023 POINT Biopharma Global Inc. PNT New Coverage Buy
(N/A)
9.24
(12.50)
35.28% Details
5/29/2023 Annexon Biosciences ANNX Maintain Buy
(N/A)
 
 
  Details
5/16/2023 Savara SVRA New Coverage Buy
(N/A)
1.99
(5.12)
157.29% Details
3/7/2023 Lexicon Pharmaceuticals LXRX New Coverage Hold
(N/A)
2.68
(2.54)
-5.22% Details
12/19/2022 Vertex VRTX Downgrade Hold
(Buy)
308.40
(430.11)
39.46% Details
11/9/2022 Marinus Pharmaceuticals MRNS Maintain Buy
(N/A)
 
 
  Details
7/22/2022 VistaGen Therapeutics VTGN Downgrade Hold
(Buy)
1.07
(4.94)
361.68% Details
7/6/2022 Vertex VRTX Maintain Buy
(N/A)
 
 
  Details
6/23/2022 Athira Pharma ATHA Downgrade Hold
(Buy)
8.45
(3.93)
-53.49% Details
6/21/2022 Xenon Pharmaceuticals XENE Maintain Buy
(N/A)
 
 
  Details
5/31/2022 Vertex VRTX Maintain Buy
(N/A)
 
 
  Details
5/11/2022 Intra-Cellular Therapies ITCI Maintain Buy
(N/A)
 
 
  Details
3/31/2022 atai Life Sciences N.V ATAI Maintain Buy
(N/A)
 
 
  Details
3/2/2022 Intra-Cellular Therapies ITCI Maintain Buy
(N/A)
 
 
  Details
2/1/2022 Vigil Neuroscience Inc VIGL New Coverage Buy
(N/A)
14.65
(3.13)
-78.63% Details
1/25/2022 Intra-Cellular Therapies ITCI Maintain Buy
(N/A)
 
 
  Details
12/20/2021 Intra-Cellular Therapies ITCI Maintain Buy
(N/A)
 
 
  Details
10/21/2021 Intra-Cellular Therapies ITCI Maintain Buy
(N/A)
 
 
  Details
10/18/2021 Intra-Cellular Therapies ITCI Maintain Buy
(N/A)
 
 
  Details
10/18/2021 Xenon Pharmaceuticals XENE Maintain Buy
(N/A)
 
 
  Details
10/4/2021 Xenon Pharmaceuticals XENE Maintain Buy
(N/A)
 
 
  Details
9/20/2021 Intra-Cellular Therapies ITCI Maintain Buy
(N/A)
 
 
  Details
9/1/2021 atai Life Sciences N.V ATAI New Coverage Buy
(N/A)
15.93
(1.83)
-88.51% Details
8/30/2021 Xenon Pharmaceuticals XENE Maintain Buy
(N/A)
 
 
  Details
8/9/2021 Xenon Pharmaceuticals XENE Maintain Buy
(N/A)
 
 
  Details
6/30/2021 VistaGen Therapeutics VTGN Maintain Buy
(N/A)
 
 
  Details
6/30/2021 Minerva Neurosciences NERV New Coverage Hold
(N/A)
2.41
(6.87)
185.06% Details
6/8/2021 Athira Pharma ATHA Maintain Buy
(N/A)
 
 
  Details
4/19/2021 Sage Therapeutics SAGE Maintain Buy
(N/A)
 
 
  Details
4/19/2021 Intra-Cellular Therapies ITCI Maintain Buy
(N/A)
 
 
  Details
4/16/2021 Athira Pharma ATHA Maintain Buy
(N/A)
 
 
  Details
4/1/2021 Xenon Pharmaceuticals XENE Maintain Buy
(N/A)
 
 
  Details
3/10/2021 Marinus Pharmaceuticals MRNS Maintain Buy
(N/A)
 
 
  Details
2/26/2021 Intra-Cellular Therapies ITCI Maintain Buy
(N/A)
 
 
  Details
2/18/2021 VistaGen Therapeuticsen Therapeutics VTGN New Coverage Buy
(N/A)
1.99
(4.94)
148.24% Details
12/21/2020 Athira Pharma ATHA Maintain Buy
(N/A)
 
 
  Details
11/6/2020 Sage Therapeutics SAGE Maintain Buy
(N/A)
 
 
  Details
10/13/2020 Athira Pharma ATHA New Coverage Buy
(N/A)
16.81
(3.93)
-76.62% Details
9/15/2020 Marinus Pharmaceuticals MRNS Maintain Buy
(N/A)
 
 
  Details
5/31/2020 Xenon Pharmaceuticals XENE New Coverage Buy
(N/A)
12.70
(49.46)
289.45% Details
1/27/2020 Relmada Therapeutics Inc RLMD New Coverage Buy
(N/A)
40.66
(5.68)
-86.03% Details
9/16/2019 Zynerba Pharmaceuticals ZYNE New Coverage Hold
(N/A)
12.19
(1.30)
-89.34% Details
8/12/2019 Intra-Cellular Therapies ITCI New Coverage Buy
(N/A)
9.23
(70.16)
660.13% Details
7/23/2019 Marinus Pharmaceuticals MRNS Maintain Buy
(N/A)
 
 
  Details
4/25/2019 Sage Therapeutics SAGE New Coverage Buy
(N/A)
166.98
(22.01)
-86.82% Details
3/5/2019 Marinus Pharmaceuticals MRNS New Coverage Buy
(N/A)
3.49
(9.77)
179.94% Details